Clinical Policy: Endothelin Receptor Antagonists-ETRA (Letairis, Opsumit, Tracleer)
Customize your policy alerts
Sign up for Arizona Complete Health Policy AZ.CP.PHAR.1012 alerts
Get alerted when Policy AZ.CP.PHAR.1012 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity criteria for ambrisentan (Letairis), bosentan (Tracleer), and macitentan (Opsumit) for Arizona Medicaid members with pulmonary arterial hypertension, including preferred-product requirements, sequencing, clinical criteria, documentation, contraindications, and approval durations.
The 1Q 2020 annual review added maximum quantity per day information for the covered drugs.
The 1Q 2022 annual review reported no significant changes and reviewed the references.
The policy history added wording specifying that the criteria also apply to Care1st.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.